DGAP-News: Epigenomics AG / Key word(s): Miscellaneous02.03.2020 / 08:00 The issuer is solely responsible for the content of this announcement. Centers for Medicare & Medicaid Services open NCD review process for Epi Pro Colon Opening of review process guarantees reimbursement decision within next nine months Results of microsimulation model published in November 2019 show competitiveness […]
Category: Press Releases
02. March 2020
Centers for Medicare & Medicaid Services open NCD review process for Epi Pro Colon
Read more
02. December 2019
Epigenomics AG: Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer
DGAP-News: Epigenomics AG / Key word(s): Study results/Study02.12.2019 / 11:37 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer Adherence rates and screening intervals recognized as […]
29. November 2019
Epigenomics AG: New Micro-Simulation Study in Cancer Medicine Finds Epi proColon(R) Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer
DGAP-News: Epigenomics AG / Key word(s): Study results/Study29.11.2019 / 15:00 The issuer is solely responsible for the content of this announcement. New Micro-Simulation Study in Cancer Medicine Finds Epi proColon(R) Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer Adherence rates and screening intervals recognized as decisive elements of successful screening strategies Berlin […]
19. November 2019
Epigenomics AG Reports Financial Results for the First Nine Months 2019
DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/9 Month figures19.11.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for the First Nine Months 2019 Berlin (Germany) and San Diego, CA (USA), November 19, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) […]
15. November 2019
Epigenomics AG Announces Conference Call with Authors Presenting at the European Public Health Conference
DGAP-News: Epigenomics AG / Key word(s): Scientific publication/Conference15.11.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Announces Conference Call with Authors Presenting at the European Public Health Conference Berlin (Germany) and San Diego, CA (U.S.A.), November 15, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced […]
04. November 2019
Epigenomics AG: No operational reasons for sharp decline in share price
DGAP-News: Epigenomics AG / Key word(s): Statement/Capital Increase 04.11.2019 / 20:55 The issuer is solely responsible for the content of this announcement. Epigenomics AG: No operational reasons for sharp decline in share price Berlin (Germany) and San Diego, CA (U.S.A.), 4 November, 2019 – The Epigenomics share price today recorded a decline of around 16% […]